Actively Recruiting
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
Led by Masonic Cancer Center, University of Minnesota · Updated on 2026-01-06
50
Participants Needed
1
Research Sites
903 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure. The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines.
CONDITIONS
Official Title
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with primary graft failure defined as not achieving an ANC 20.5x10^9/L for three consecutive days by day 35-42 after first transplant
- Patients with secondary graft failure defined as achieving an ANC 20.5x10^9/L for three consecutive days by day 35-42 but subsequently dropping below 0.5x10^9/L without recovery
- Patients with loss of chimerism defined as achieving an ANC 20.5x10^9/L for three consecutive days but with less than 10% CD15+ donor cells in marrow or blood
- Acceptable renal function: creatinine < 2.0 (adults) and creatinine clearance > 30; dose adjustments if creatinine clearance < 70
- Acceptable hepatic function: bilirubin, AST/ALT, ALP < 10 times upper limit of normal
- Acceptable cardiac function: left ventricular ejection fraction > 40%
You will not qualify if you...
- Uncontrolled infection at the time of transplant
- Diagnosis of Fanconi Anemia or other DNA breakage syndromes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
Research Team
T
Timothy Krepski
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here